Format

Send to

Choose Destination
Oncotarget. 2017 Apr 18;8(16):26789-26801. doi: 10.18632/oncotarget.15817.

The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.

Author information

1
Department of Medical Biology, UiT The Arctic University of Norway, N-9037 Tromso, Norway.
2
Department of Clinical Medicine, UiT The Arctic University of Norway, N-9037 Tromso, Norway.
3
Department of Oncology, University Hospital of North Norway, N-9038 Tromso, Norway.
4
Department of Clinical Pathology, University Hospital of North Norway, N-9038 Tromso, Norway.
5
Department of Urology, University Hospital of North Norway, N-9038 Tromso, Norway.

Abstract

Programmed cell death protein 1 (PD-1) and its ligand Programmed death ligand 1 (PD-L1) have gained massive attention in cancer research due to recent availability and their targeted antitumor effects. Their role in prostate cancer is still undetermined. We constructed tissue microarrays from prostatectomy specimens from 535 prostate cancer patients. Following validation of antibodies, immunohistochemistry was used to evaluate the expression of PD-1 in lymphocytes and PD-L1 in epithelial and stromal cells of primary tumors. PD-L1 expression was commonly seen in tumor epithelial cells (92% of cases). Univariate survival analysis revealed a positive association between a high density of PD-1+ lymphocytes and worse clinical failure-free survival, limited to a trend (p = 0.084). In subgroups known to indicate unfavorable prostate cancer prognosis (Gleason grade 9, age < 65, preoperative PSA > 10, pT3) patients with high density of PD-1+ lymphocytes had a significantly higher risk of clinical failure (p = < 0.001, p = 0.025, p = 0.039 and p = 0.011, respectively). In the multivariate analysis, high density of PD-1+ lymphocytes was a significant negative independent prognostic factor for clinical failure-free survival (HR = 2.48, CI 95% 1.12-5.48, p = 0.025).

KEYWORDS:

PD-1; PDL-1; immunohistochemistry; prognostic marker; prostate cancer

PMID:
28460462
PMCID:
PMC5432297
DOI:
10.18632/oncotarget.15817
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center